Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 34 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/18/2008 First Published: 12/1/1998


1.		Phase III Randomized Study of Gadolinium Texaphyrin as a Radiosensitizer in Patients With Brain Metastases Receiving Whole Brain Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				PCI-P120-9801 MSKCC-00088, UCLA-9808021, NCI-V98-1470, NCT00003563

Last Modified: 6/13/2006 First Published: 7/26/2003


2.		Phase III Randomized Study of Motexafin Gadolinium and Whole Brain Radiotherapy Versus Whole Brain Radiotherapy Alone in Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0302038 PCI-P-PCYC-0211, NCT00054795

Last Modified: 5/1/1998


3.		Phase IB/II Study of Gadolinium Texaphyrin (PCI-0120) Radiosensitization for Palliative Radiotherapy of Brain Metastases (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				PCI-P120-9501 NCI-V96-0844

Last Modified: 1/21/2008 First Published: 7/23/2004


4.		Phase I/II Study of Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Bulky Stage II or Stage III or IV Relapsed or Refractory CD20-Positive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				NU-02H8 NU-0228-024, PCI-P-PCYC-0213, NCT00089284


5.		Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				PCYC-0223 NCT00290004

Last Modified: 10/1/2001 First Published: 8/1/2001


6.		Phase II Study of Motexafin Gadolinium and Cranial Irradiation in Patients With Newly Diagnosed Glioblastoma Multiforme (Summary Last Modified 10/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-01051 PCI-PCYC-0206, NCI-G01-1999, NCT00022256


7.		A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				PCYC-0216 NCT00076401


8.		Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				PCYC-0221 NCT00086034


9.		A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				PCYC-0215 NCT00096837


10.		Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				PCYC-0222 NCT00100711

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute